U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C18H24NO4
Molecular Weight 318.3875
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 7
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of METHSCOPOLAMINE

SMILES

C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]3O[C@@H]23)OC(=O)[C@H](CO)C4=CC=CC=C4

InChI

InChIKey=LZCOQTDXKCNBEE-IKIFYQGPSA-N
InChI=1S/C18H24NO4/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11/h3-7,12-17,20H,8-10H2,1-2H3/q+1/t12-,13-,14-,15+,16-,17+/m1/s1

HIDE SMILES / InChI

Molecular Formula C18H23NO4
Molecular Weight 317.3795
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 6 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Methscopolamine bromide is an anticholinergic agent used along with other medications to treat peptic ulcers by reducing stomach acid secretion. Methscopolamine is also commonly used as a drying agent, to dry up post-nasal drip, in cold, irritable bowel syndrome and allergy medications. Methscopolamine binds to M1-M5 isoforms of muscarinic receptors.

CNS Activity

Curator's Comment: Methscopolamine bromide has limited ability to cross the blood-brain-barrier

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PAMINE

Approved Use

Methscopolamine bromide is an anticholinergic agent which possesses most of the pharmacological actions of that drug class. These include reduction in volume and total acid content of gastric secretion, inhibition of gastrointestinal motility, inhibition of salivary excretion, dilation of the pupil and inhibition of accommodation with resulting blurring of vision. Large doses may result in tachycardia.

Launch Date

1953
Palliative
DALLERGY

Approved Use

This product provides relief of the symptoms resulting from irritation of sinus, nasal, and upper respiratory tract tissue. Phenylephrine exerts a vasoconstrictive and decongestive action while chlorpheniramine maleate decreases the symptoms of watering eyes, post nasal drip, and sneezing. Methscopolamine nitrate further augments the antisecretory activity of this product.
Palliative
DALLERGY

Approved Use

This product provides relief of the symptoms resulting from irritation of sinus, nasal, and upper respiratory tract tissue. Phenylephrine exerts a vasoconstrictive and decongestive action while chlorpheniramine maleate decreases the symptoms of watering eyes, post nasal drip, and sneezing. Methscopolamine nitrate further augments the antisecretory activity of this product.
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Zinc oxide nanoparticle disruption of store-operated calcium entry in a muscarinic receptor signaling pathway.
2010-10
Attenuation of cocaine's reinforcing and discriminative stimulus effects via muscarinic M1 acetylcholine receptor stimulation.
2010-03
Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
2006-08
Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity.
2006-07
Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7.
2006-05
Allosteric site in M2 acetylcholine receptors: evidence for a major conformational change upon binding of an orthosteric agonist instead of an antagonist.
2006-01
Modifications in muscarinic, dopaminergic and serotonergic receptors concentrations in the hippocampus and striatum of epileptic rats.
2005-12-05
Critical amino acid residues of the common allosteric site on the M2 muscarinic acetylcholine receptor: more similarities than differences between the structurally divergent agents gallamine and bis(ammonio)alkane-type hexamethylene-bis-[dimethyl-(3-phthalimidopropyl)ammonium]dibromide.
2005-09
Asparagine, valine, and threonine in the third extracellular loop of muscarinic receptor have essential roles in the positive cooperativity of strychnine-like allosteric modulators.
2005-05
Pilocarpine-induced seizures in adult rats: monoamine content and muscarinic and dopaminergic receptor changes in the striatum.
2003-10
Bisquaternary dimers of strychnine and brucine. A new class of potent enhancers of antagonist binding to muscarinic M2 receptors.
2003-06-12
Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors.
2002-12
Zebrafish M2 muscarinic acetylcholine receptor: cloning, pharmacological characterization, expression patterns and roles in embryonic bradycardia.
2002-11
Allosteric interactions of staurosporine and other indolocarbazoles with N-[methyl-(3)H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site.
2000-07
A snake venom inhibitor to muscarinic acetylcholine receptor (mAChR): isolation and interaction with cloned human mAChR.
2000-05-15
Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors.
1999
Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells.
1998-11
Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies.
1998-03
Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors.
1997-07
Central cholinergic mechanisms in L-DOPA induced hyperactive urinary bladder of the rat.
1982
Effect of cholingeric drugs on methadone-induced catalepsy and stereotypies in rats treated chronically with methadone.
1976-10
Patents

Patents

Sample Use Guides

The average dosage of Methscopolamine Bromide Tablets USP is 2.5 mg one-half hour before meals and 2.5 to 5 mg at bedtime. A starting dose of 12.5 mg daily will be clinically effective in most patients without the production of appreciable side effects.
Route of Administration: Oral
In Vitro Use Guide
In the standard assay, mAChR subtypes (20-30 fmol/tube) in particulate fractions of Sf9 cells were incubated with 4 to 4.2 nM [3H]NMS (methscopolamine) and different concentrations of muscarinic ligands in 20 mM K-phosphate buffer (pH 7). Bound [3H]NMS trapped on the filter was counted with a liquid scintillation counter.
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:14:40 GMT 2025
Edited
by admin
on Mon Mar 31 18:14:40 GMT 2025
Record UNII
VDR09VTQ8U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
METHSCOPOLAMINE
VANDF  
Common Name English
METHYLSCOPOLAMINE
WHO-DD  
Preferred Name English
N-METHYLHYOSCINE
Common Name English
N-METHYLSCOPOLAMINE
Common Name English
METHSCOPOLAMINE [VANDF]
Common Name English
METHSCOPOLAMINE ION
Common Name English
3-OXA-9-AZONIATRICYCLO(3.3.1.02,4)NONANE, 7-(3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-9,9-DIMETHYL-, (7(S)-(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.))-
Systematic Name English
(-)-N-METHYLSCOPOLAMINE
Common Name English
Methylscopolamine [WHO-DD]
Common Name English
METHSCOPOLAMINE CATION
Common Name English
3-OXA-9-AZONIATRICYCLO(3.3.1.02,4)NONANE, 7-((2S)-3-HYDROXY-1-OXO-2-PHENYLPROPOXY)-9,9-DIMETHYL-, (1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.)-
Systematic Name English
Classification Tree Code System Code
LIVERTOX 621
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
WHO-ATC S01FA03
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
NDF-RT N0000175370
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
WHO-ATC A03BB03
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
WHO-VATC QS01FA03
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
WHO-ATC A03CB01
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
WHO-VATC QA03BB03
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
WHO-VATC QA03CB01
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
NCI_THESAURUS C29704
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
NDF-RT N0000175574
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
Code System Code Type Description
EVMPD
SUB32123
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
PRIMARY
DRUG BANK
DB11315
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
PRIMARY
CAS
13265-10-6
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
PRIMARY
SMS_ID
100000124342
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
PRIMARY
MESH
D019832
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
PRIMARY
NCI_THESAURUS
C76001
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
PRIMARY
DRUG CENTRAL
1757
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
PRIMARY
FDA UNII
VDR09VTQ8U
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
PRIMARY
HSDB
5420
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
PRIMARY
WIKIPEDIA
Methscopolamine
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
PRIMARY
DAILYMED
VDR09VTQ8U
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
PRIMARY
EPA CompTox
DTXSID0046931
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
PRIMARY
RXCUI
89785
Created by admin on Mon Mar 31 18:14:40 GMT 2025 , Edited by admin on Mon Mar 31 18:14:40 GMT 2025
PRIMARY RxNorm
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY